BR112017012483A2 - composição aquosa - Google Patents

composição aquosa

Info

Publication number
BR112017012483A2
BR112017012483A2 BR112017012483-1A BR112017012483A BR112017012483A2 BR 112017012483 A2 BR112017012483 A2 BR 112017012483A2 BR 112017012483 A BR112017012483 A BR 112017012483A BR 112017012483 A2 BR112017012483 A2 BR 112017012483A2
Authority
BR
Brazil
Prior art keywords
aqueous composition
salt
compound
blocker
discoloration
Prior art date
Application number
BR112017012483-1A
Other languages
English (en)
Inventor
Suzuki Yuuki
Sawai Isamu
Oda Hiroshi
Original Assignee
Kowa Company, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Company, Ltd. filed Critical Kowa Company, Ltd.
Publication of BR112017012483A2 publication Critical patent/BR112017012483A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

trata-se de uma técnica que é fornecida para reduzir a descoloração de uma composição aquosa contendo um derivado de isoquinolina halogenada durante a conservação à alta temperatura. uma composição aquosa que compreende um composto representado pela fórmula (1): em que x representa um átomo de halogênio, ou um sal do mesmo, ou um solvato do composto ou o sal do mesmo, e a ¿ bloqueador.
BR112017012483-1A 2014-12-12 2015-12-11 composição aquosa BR112017012483A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP2014252192 2014-12-12
JP2014251697 2014-12-12
JP2014-251697 2014-12-12
JP2014-251695 2014-12-12
JP2014-252192 2014-12-12
JP2014251695 2014-12-12
PCT/JP2015/084804 WO2016093346A1 (ja) 2014-12-12 2015-12-11 水性組成物

Publications (1)

Publication Number Publication Date
BR112017012483A2 true BR112017012483A2 (pt) 2018-01-09

Family

ID=56107523

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017012483-1A BR112017012483A2 (pt) 2014-12-12 2015-12-11 composição aquosa

Country Status (11)

Country Link
US (1) US20170367977A1 (pt)
EP (1) EP3231431A4 (pt)
JP (2) JP5951922B1 (pt)
KR (1) KR20170093839A (pt)
CN (1) CN107106570B (pt)
BR (1) BR112017012483A2 (pt)
CA (1) CA2970275A1 (pt)
MX (1) MX2017007572A (pt)
MY (1) MY178370A (pt)
SG (1) SG11201704740WA (pt)
WO (1) WO2016093346A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3335872A1 (en) * 2016-12-16 2018-06-20 Amcor Flexibles Winterbourne Limited Polymeric films and packages produced therefrom
KR102308566B1 (ko) * 2019-05-28 2021-10-05 서울대학교병원 녹내장 안약의 약물이상반응 진단 키트
JP2020200296A (ja) * 2019-06-13 2020-12-17 久貴 藤本 角膜内皮障害の予防及び／又は治療のための薬剤
EP4281040A1 (en) * 2021-01-21 2023-11-29 Kowa Company, Ltd. Methods of treating fuchs endothelial corneal dystrophy after descemetorhexis
CN114796219A (zh) * 2022-05-18 2022-07-29 沈阳药科大学 一种用于治疗青光眼的复方药物组合物及其用途
KR102552116B1 (ko) 2022-05-26 2023-07-05 이근형 Uv 반사경화를 이용한 uv성형 인쇄시트

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4000505B2 (ja) * 1999-12-01 2007-10-31 第一三共株式会社 緑内障を治療するための併用剤
WO2002022106A2 (en) * 2000-09-14 2002-03-21 Novartis Ag Stable ophthalmic preparation
WO2004045644A1 (ja) * 2002-11-18 2004-06-03 Santen Pharmaceutical Co., Ltd. Rhoキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤
US7718797B2 (en) * 2004-03-16 2010-05-18 Asahi Kasei Pharma Corporation Fasudil-containing preparation and method of improving stability thereof
WO2006115244A1 (ja) * 2005-04-25 2006-11-02 D. Western Therapeutics Institute, Inc. ４－ブロモイソキノリン誘導体及びこれを含有する医薬
KR101333970B1 (ko) * 2005-05-19 2013-11-27 코와 가부시키가이샤 녹내장 예방 또는 치료제
JP2006348028A (ja) * 2005-05-19 2006-12-28 Kowa Co 緑内障予防又は治療剤
JP4800720B2 (ja) * 2005-09-21 2011-10-26 興和株式会社 点眼用組成物
JP2013035802A (ja) * 2011-08-10 2013-02-21 D Western Therapeutics Institute Inc 緑内障又は高眼圧症の予防又は治療剤
CN108743587B (zh) * 2014-01-10 2021-04-30 参天制药株式会社 含有吡啶基氨基乙酸化合物的药物制剂

Also Published As

Publication number Publication date
KR20170093839A (ko) 2017-08-16
WO2016093346A1 (ja) 2016-06-16
CA2970275A1 (en) 2016-06-16
MX2017007572A (es) 2018-02-09
EP3231431A1 (en) 2017-10-18
US20170367977A1 (en) 2017-12-28
JP2016183181A (ja) 2016-10-20
EP3231431A4 (en) 2018-08-01
CN107106570B (zh) 2021-02-05
CN107106570A (zh) 2017-08-29
JPWO2016093346A1 (ja) 2017-04-27
MY178370A (en) 2020-10-09
JP5951922B1 (ja) 2016-07-13
SG11201704740WA (en) 2017-07-28

Similar Documents

Publication Publication Date Title
BR112017012483A2 (pt) composição aquosa
BR112017006148A2 (pt) produto farmacêutico
BR112017012491A2 (pt) composição
BR112017012487A2 (pt) composição aquosa
BR112018011475A2 (pt) compostos e métodos para modulação de quinase e indicação para a mesma
BR112017006253A2 (pt) novos compostos
BR112017002827A2 (pt) derivado de quinolina altamente puro e método para produção do mesmo
CU20160052A7 (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
BR112015018188A2 (pt) composição e método para o controle de pestes
BR112017009168A2 (pt) derivado de tionucleosídeo ou sal deste e composição farmacêutica
BR112019002576A2 (pt) composto, medicamento¸ métodos para inibição de gcn2 em um mamífero e para a profilaxia ou tratamento de câncer em um mamífero, e, uso do composto ou um sal do mesmo
BR112015018738A2 (pt) compostos de tetra-hidropirrolotiazina
BR112017003898A2 (pt) análogos de dioxolano de uridina para o tratamento de câncer
MX2017003945A (es) Preparacion farmaceutica.
BR112016025356A2 (pt) 4-fenilpiperidinas substituido, sua preparação e utilização
BR112017011921A2 (pt) agente para tratamento de deformação de cabelo
AR105967A1 (es) Sales de un inhibidor de pim quinasa
BR112017004925A2 (pt) composição e método
BR112016007620A2 (pt) composto, medicamento, e, uso de um composto
BR112015024075A2 (pt) compostos de piridinilpirazoloquinolina
BR112016006153A2 (pt) composição contendo polietileno glicol
EA201692270A1 (ru) Производные нафтиридиндиона
EA201990313A1 (ru) Производное триазолопиразинона, пригодное в качестве ингибитора фдэ1 человека
BR112017006150A2 (pt) composição aquosa
AR093827A1 (es) Agentes antibacterianos de tetrahidroquinolina triciclica

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2700 DE 04-10-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.